Recognition of Non-Operating Income (Grant Income and Foreign Exchange Gains) and an Extraordinary Loss (Impairment Loss on Fixed Assets)
RIBOMIC Inc. (filing company)
The achondroplasia treatment umedaptanib pegol, foreign-currency holdings of the Company, and fixed assets held by the Company
The grant income resulted from completion of the final inspection of the grant associated with umedaptanib pegol receiving orphan drug designation. The foreign exchange gain resulted from the yen weakening against foreign currencies. The impairment loss resulted from impairment treatment based on the accounting standard for impairment of fixed assets.
Grant income of ¥39.160 million (non-operating income), a foreign exchange gain of ¥26 thousand (non-operating income), and an impairment loss of ¥5.578 million (extraordinary loss). In addition, the cumulative foreign exchange loss for the fiscal year ending March 2026 was ¥98 thousand.
Fourth-quarter accounting period of the fiscal year ending March 2026 (1 January 2026 to 31 March 2026)
Please refer to the “Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)” released today.
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income (Grant Income and Foreign Exchange Gains) and an Extraordinary Loss (Impairment Loss on Fixed Assets) |
| Date of occurrence | Fourth-quarter accounting period of the fiscal year ending March 2026 (1 January 2026 to 31 March 2026) |
| Subject Entity | RIBOMIC Inc. (filing company) |
| Target Locations / Products | The achondroplasia treatment umedaptanib pegol, foreign-currency holdings of the Company, and fixed assets held by the Company |
| Cause | The grant income resulted from completion of the final inspection of the grant associated with umedaptanib pegol receiving orphan drug designation. The foreign exchange gain resulted from the yen weakening against foreign currencies. The impairment loss resulted from impairment treatment based on the accounting standard for impairment of fixed assets. |
| Amount of Impact on Business Performance | Grant income of ¥39.160 million (non-operating income), a foreign exchange gain of ¥26 thousand (non-operating income), and an impairment loss of ¥5.578 million (extraordinary loss). In addition, the cumulative foreign exchange loss for the fiscal year ending March 2026 was ¥98 thousand. |
| Accounting period in which recognized | Fourth-quarter accounting period of the fiscal year ending March 2026 (1 January 2026 to 31 March 2026) |
| Impact on Earnings Forecast | Please refer to the “Summary of Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)” released today. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The grant income was recognized because the final inspection of the grant associated with umedaptanib pegol receiving orphan drug designation was completed. The foreign exchange gain arose because the depreciation of the yen generated valuation gains on foreign-currency holdings. The impairment loss was recognized based on the accounting standard for impairment of fixed assets.